PROTACpedia
The search can be performed by various parameters such as Target name, UniProt ID, SMILES substructure or by various details regarding a publication.
Note that it is possible to narrow down the search results by querying several fields simultaneously.

The resulting PROTAC images are color coded: green - E3 binder, red - linker, blue - target binding ligand.
If you find this web server of interest, please also try PRosettaC.
Gene or Target name
UniProt Id
Ligand name
E3 Ligase
E3 Binder
PROTAC SMILES (substructure)
PROTAC Name
Author
Year
Pubmed or Patent number
Curator
Algorithm and overview: Nir London (nir.london@weizmann.ac.il)
Server: Jaime Prilusky (jaime.prilusky@weizmann.ac.il)
5 Representative
+50 Active PROTACs
+8 Inactive PROTACs
 DetailsDC50DmaxSource
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5904-8. PMID:18752944 DOI:10.1016/j.bmcl.2008.07.114
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg Med Chem. 2011 Nov 15;19(22):6768-78. PMID:22014751 DOI:10.1016/j.bmc.2011.09.041
= 5 nM= 98 % Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100. PMID:30271980 DOI:10.1038/s42003-018-0105-8
= 15 nM= 76 % Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100. PMID:30271980 DOI:10.1038/s42003-018-0105-8
= 47 % Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100. PMID:30271980 DOI:10.1038/s42003-018-0105-8
< 10.4 nM> 95 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 87 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 35 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 87 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 80 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 89 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 94 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 40 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 97 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 65 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 93 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 35 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 88 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 93 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 75 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 84 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 95 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 92 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 86 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 33 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 99 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 100 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 31 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 99 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 96 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 78 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 96 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 20 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 12 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 25 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 25 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 29 % Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. PMID:30629437 DOI:10.1021/acs.jmedchem.8b01631
= 0.5352 nM> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
= 7.2 nM> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
= 68 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
= 86 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 95 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
> 99 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
< 5 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
= 11 % Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. PMID:31804827 DOI:10.1021/acs.jmedchem.9b01393
= 8.0 nM Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia. 2020 Jan 10;22(2):111-119. PMID:31931431 DOI:10.1016/j.neo.2019.12.003
Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia. 2020 Jan 10;22(2):111-119. PMID:31931431 DOI:10.1016/j.neo.2019.12.003
Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia. 2020 Jan 10;22(2):111-119. PMID:31931431 DOI:10.1016/j.neo.2019.12.003
Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia. 2020 Jan 10;22(2):111-119. PMID:31931431 DOI:10.1016/j.neo.2019.12.003